Y Intercept Hong Kong Ltd Sells 6,475 Shares of DaVita Inc. $DVA

Y Intercept Hong Kong Ltd lowered its position in DaVita Inc. (NYSE:DVA) by 74.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,250 shares of the company’s stock after selling 6,475 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in DaVita were worth $299,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. Hantz Financial Services Inc. increased its stake in DaVita by 48.1% in the 2nd quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares during the last quarter. MAI Capital Management grew its holdings in shares of DaVita by 23.4% during the second quarter. MAI Capital Management now owns 438 shares of the company’s stock worth $62,000 after purchasing an additional 83 shares in the last quarter. NewEdge Advisors LLC increased its position in shares of DaVita by 20.8% in the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after purchasing an additional 88 shares during the last quarter. Teacher Retirement System of Texas raised its stake in DaVita by 1.4% in the second quarter. Teacher Retirement System of Texas now owns 6,696 shares of the company’s stock valued at $954,000 after purchasing an additional 94 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in DaVita by 1.2% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 10,184 shares of the company’s stock valued at $1,451,000 after purchasing an additional 122 shares during the last quarter. Institutional investors own 90.12% of the company’s stock.

Wall Street Analyst Weigh In

DVA has been the topic of several research reports. Barclays raised their price objective on shares of DaVita from $143.00 to $158.00 and gave the company an “equal weight” rating in a research report on Tuesday. Zacks Research raised DaVita from a “hold” rating to a “strong-buy” rating in a research note on Wednesday. Wall Street Zen lowered DaVita from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Truist Financial set a $158.00 price objective on DaVita in a research report on Thursday. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of DaVita in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $160.50.

DaVita Trading Up 5.2%

NYSE DVA opened at $149.42 on Friday. The firm has a market cap of $10.55 billion, a PE ratio of 15.08, a price-to-earnings-growth ratio of 0.50 and a beta of 0.99. DaVita Inc. has a 1-year low of $101.00 and a 1-year high of $178.38. The stock has a 50-day moving average of $114.70 and a 200-day moving average of $125.11.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Monday, February 2nd. The company reported $3.40 EPS for the quarter, topping analysts’ consensus estimates of $3.24 by $0.16. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The business had revenue of $3.62 billion for the quarter, compared to analysts’ expectations of $3.51 billion. During the same period in the previous year, the firm earned $2.24 EPS. The business’s quarterly revenue was up 9.9% on a year-over-year basis. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. As a group, equities research analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Trending Headlines about DaVita

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: Q1 earnings beat and revenue beat drove the immediate market move; street coverage says the results and management commentary explain the gap?up. DaVita (NYSE:DVA) Shares Gap Up After Strong Earnings
• Positive Sentiment: News summaries and market stories point to the same drivers (earnings, guidance and volume) as the reason the stock is “rocketing” higher. Why Is DaVita (DVA) Stock Rocketing Higher Today
• Positive Sentiment: Transcript coverage of the Q1 call provides detail on results and FY guidance (management set FY2026 EPS guidance), reinforcing investor confidence in cash flow and earnings trajectory. DaVita (DVA) Q1 2025 Earnings Call Transcript
• Positive Sentiment: Value-oriented outlets (Zacks) are highlighting DVA as a long?term value idea and discussing the stock in the context of earnings-estimate strength, supporting greater retail/institutional interest. Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term
• Positive Sentiment: Additional Zacks coverage frames DVA as attractive to value investors based on earnings revisions and style scores, which can drive further interest from that investor cohort. Should Value Investors Buy DaVita (DVA) Stock?
• Positive Sentiment: DVA is being featured in thematic/retirement stock lists (Buffett?style picks), which can lift retail demand and perception of DVA as a long?term holding. 3 Warren Buffett-Style Stocks for a Golden Retirement
• Neutral Sentiment: Industry/strategic news: an item on Elara Caring and Ares’ backing mentions DaVita in the kidney care ecosystem — relevant to strategic positioning but not an immediate earnings catalyst. Elara Caring Backed By Ares’ Private Equity Group, Kidney Care Provider DaVita
• Neutral Sentiment: Context pieces exploring DVA within the DJIA healthcare space provide useful comparative data but are informational rather than near?term catalysts. Explore DaVita Within Dow Jones Industrial Average Healthcare Space
• Negative Sentiment: Several analysts are mixed on DVA’s outlook; divergent analyst views could cap upside if estimates or sentiment turn less favorable. Analysts’ Opinions Are Mixed on These Healthcare Stocks: Boston Scientific (BSX) and DaVita (DVA)

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.